Ligand Pharmaceuticals Incorporated (LGND) — Cash Flow-to-Debt Ratio
Ligand Pharmaceuticals Incorporated (LGND) has a Cash Flow-to-Debt Ratio of 0.02x as of June 2026, meaning its operating cash flow of $24.02 Million could theoretically repay 0% of its total liabilities ($1.22 Billion) in one year. See Ligand Pharmaceuticals Incorporated (LGND) flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Ligand Pharmaceuticals Incorporated Cash Flow-to-Debt Ratio (1994–2025)
Historical debt coverage capacity for Ligand Pharmaceuticals Incorporated across 32 annual periods. For the full cash flow conversion analysis, see how efficiently does Ligand Pharmaceuticals Incorporated generate cash.
Annual Cash Flow-to-Debt Ratio for Ligand Pharmaceuticals Incorporated (1994–2025)
Year-by-year debt coverage analysis for Ligand Pharmaceuticals Incorporated. Check LGND cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.09x | $49.36 Million | $543.42 Million | ▼ -89.6% |
| 2024 | 0.87x | $97.05 Million | $111.33 Million | ▲ +51.7% |
| 2023 | 0.57x | $49.58 Million | $86.30 Million | ▼ -31.2% |
| 2022 | 0.83x | $137.85 Million | $165.18 Million | ▲ +404.6% |
| 2021 | 0.17x | $78.80 Million | $476.43 Million | ▲ +97.8% |
| 2020 | 0.08x | $54.59 Million | $652.76 Million | ▲ +307.4% |
| 2019 | -0.04x | $-29.34 Million | $727.68 Million | ▼ -114.5% |
| 2018 | 0.28x | $194.06 Million | $699.89 Million | ▼ -25.2% |
| 2017 | 0.37x | $93.57 Million | $252.37 Million | ▲ +35.8% |
| 2016 | 0.27x | $63.00 Million | $230.73 Million | ▲ +50.2% |
| 2015 | 0.18x | $41.73 Million | $229.54 Million | ▲ +106.5% |
| 2014 | 0.09x | $20.57 Million | $233.62 Million | ▼ -76.6% |
| 2013 | 0.38x | $20.69 Million | $55.10 Million | ▲ +18039.4% |
| 2012 | 0.00x | $161.00K | $77.78 Million | ▲ +120.1% |
| 2011 | -0.01x | $-1.17 Million | $113.70 Million | ▲ +96.9% |
| 2010 | -0.33x | $-27.07 Million | $82.55 Million | ▼ -6.7% |
| 2009 | -0.31x | $-33.80 Million | $109.95 Million | ▼ -171.0% |
| 2008 | -0.11x | $-20.62 Million | $181.81 Million | ▲ +83.3% |
| 2007 | -0.68x | $-97.73 Million | $144.16 Million | ▼ -46.2% |
| 2006 | -0.46x | $-138.52 Million | $298.70 Million | ▼ -2456.4% |
| 2005 | 0.02x | $8.37 Million | $425.04 Million | ▲ +39.5% |
| 2004 | 0.01x | $5.75 Million | $407.78 Million | ▲ +1087.2% |
| 2003 | 0.00x | $274.00K | $230.53 Million | ▲ +100.9% |
| 2002 | -0.13x | $-25.11 Million | $196.59 Million | ▼ -12.5% |
| 2001 | -0.11x | $-19.91 Million | $175.35 Million | ▲ +59.6% |
| 2000 | -0.28x | $-47.35 Million | $168.55 Million | ▲ +25.6% |
| 1999 | -0.38x | $-60.50 Million | $160.20 Million | ▲ +5.1% |
| 1998 | -0.40x | $-66.60 Million | $167.40 Million | ▼ -117.0% |
| 1997 | -0.18x | $-13.40 Million | $73.10 Million | ▲ +62.8% |
| 1996 | -0.49x | $-33.30 Million | $67.60 Million | ▲ +14.9% |
| 1995 | -0.58x | $-37.90 Million | $65.50 Million | ▲ +17.5% |
| 1994 | -0.70x | $-14.30 Million | $20.40 Million | — |